Ensovibep is shown in vitro to maintain inhibition against all variants of concern known to dateThe Company is also presenting a Trial in Progress poster on the EMPATHY clinical...
Novartis (NVS) announces data demonstrating the safety of Kesimpta (ofatumumab) over extended exposure (~3.5 years) in patients with relapsing forms of multiple sclerosis...
Novartis (NVS) on Wednesday announced that the FDA has accepted its supplemental Biologics License Application (sBLA) and that the EMA has validated the type-II variation...
US futures and European stocks rally with cyclicalsUS stocks enjoyed the strongest day since March yesterdayBitcoin recoversKey EventsUS futures on the Dow, S&P, NASDAQ and...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Neutral | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Buy | Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 596.00 | 597.60 | 590.80 | +3.40 | +0.57% | 3.40M | London | |||
| 372.00 | 373.00 | 362.00 | +7.00 | +1.92% | 124.60K | London | |||
| 3,500.00 | 3,518.00 | 3,492.00 | -18.0 | -0.51% | 73.90K | London | |||
| 4,885.50 | 4,940.50 | 4,792.50 | -164.5 | -3.26% | 3.39M | London | |||
| 3.75 | 3.54 | 3.54 | -0.0500 | -1.32% | 233.40K | London | |||
| 22.76 | 22.84 | 22.18 | +0.52 | +2.34% | 226.57K | London | |||
| 181.30 | 183.40 | 180.40 | -2.40 | -1.31% | 4.70M | London | |||
| 62.40 | 64.70 | 61.98 | -2.34 | -3.61% | 13.65M | London | |||
| 433.30 | 435.20 | 429.80 | +1.20 | +0.28% | 15.96M | London | |||
| 138.28 | 139.96 | 132.76 | -1.16 | -0.83% | 36.53M | London | |||
| 7,982.00 | 8,066.00 | 7,942.00 | -86.0 | -1.07% | 175.77K | London | |||
| 364.50 | 365.00 | 364.25 | 0.00 | 0.00% | 0.00 | London | |||
| 112.00 | 112.50 | 109.38 | +2.60 | +2.38% | 53.62M | London | |||
| 297.20 | 298.10 | 294.50 | +0.40 | +0.14% | 1.56M | London | |||
| 10.95 | 10.50 | 10.20 | +0.95 | +9.50% | 8.82M | London |
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.